<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620527</url>
  </required_header>
  <id_info>
    <org_study_id>FMI-CTDNA-15</org_study_id>
    <nct_id>NCT02620527</nct_id>
  </id_info>
  <brief_title>Concordance Between ctDNA Assay and FoundationOne</brief_title>
  <official_title>Study of Concordance Between Circulating Tumor DNA Assay and Foundation One Tissue Analysis For Genomic Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncology Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Comprehensive Blood and Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Illinois CancerCare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanford Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastchester Center for Cancer Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers Cancer Institute of New Jersey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cone Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nebraska Cancer Specialists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northeast Georgia Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hematology Oncology Associates of Fredericksburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncology Hematology Care, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quincy Medical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Greenville Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mary Crowley Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Avera Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic
      alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA
      (ctDNA) within different solid tumor types and has been developing an assay in order to do
      so.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess whether a new ctDNA assay developed by Foundation
      Medicine is able to detect genomic alterations in peripheral blood that are consistent with
      the genomic alterations detected in a patient's matched primary and/or metastatic tumor
      biopsy sample analyzed by the FoundationOne® test. Study sites will provide matched solid
      tumor and peripheral blood samples of cancer patients to FMI for the purpose of testing the
      concordance of the FMI ctDNA assay to the FoundationOne® test. Participation in this study is
      part of a broader 2000 patient study to determine which tumor types are most readily measured
      via ctDNA profiling, and to learn of the similarity between the alterations found in a
      patient's tumor biopsy and the ctDNA from their blood.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Whether new ctDNA assay can detect genomic alterations in peripheral blood that are consistent with those detected by FoundationOne in matched solid tumor samples</measure>
    <time_frame>6-12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine which tumor types are most amenable to detection using peripheral blood ctDNA assay</measure>
    <time_frame>6-12 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Circulating Tumor DNA</condition>
  <condition>Cancer</condition>
  <condition>Neoplasms</condition>
  <condition>Genomic Testing</condition>
  <condition>Genomic Alterations</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with cancer and who have had a solid tumor biopsy isolated for analysis
        by FoundationOne
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have had a solid tumor biopsy isolated for analysis by FoundationOne
             under their standard clinical care

        Exclusion Criteria:

          -  Tumor specimens where no cancer representative of the diagnosis is found in submitted
             tissue

          -  Tumor specimens where insufficient DNA (&lt;50 ng) is provided to run the FoundationOne
             test.

          -  Tumor specimens with ≤20% tumor nuclei (all specimens).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Stephens, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foundation Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Benson</last_name>
    <email>abenson@foundationmedicine.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sohail Balasubramanian</last_name>
    <email>sbalasubramanian@foundationmedicine.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foundation Medicine</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating Tumor DNA</keyword>
  <keyword>Cancer</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Genomic Testing</keyword>
  <keyword>FoundationOne</keyword>
  <keyword>Cell Free DNA</keyword>
  <keyword>ctDNA</keyword>
  <keyword>cfDNA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

